NVL-330 is a selective, brain-penetrant inhibitor of oncogenic HER2 exon 20 insertion mutations in preclinical models. (October 2022) - Andrews, K.L.; Sun, Y.; Gerard, B.; Tangpeerachaikul, A.; Mente, S.; Kemper, R.A.; Martin, C.M.; Kohl, N.E.; Horan, J.C.; Pelish, H.E.